Markets
Alison is focused on markets generally perceived to be of higher risk, but with great potential reward. Risk is relative and is significantly reduced by the experience Alison brings to its partners.
Looking ahead, the global sterile dosage form industry is expected to rise at a CAGR of 6.7% from 2023 to 2033. During the forecast period, the market size is expected to reach US$ 1.1 billion by 2033.
The market for sterile dosage forms is anticipated to continue seeing favorable growth. The ageing population, the developments in medical technology, and the increased incidence of chronic diseases are all expected to contribute to the need for biologics and injectable medications continuing to rise. The demand for sterile dosage forms will increase as personalized medicine becomes more prevalent and novel medicines and treatment choices become available. The effectiveness and quality of the production of sterile dosage forms are likely to be improved by technological developments in aseptic processing and factory automation.
Alison’s marketing policy is based on opening export markets as one of its main marketing goals. In this regard, Alison is seeking to obtain manufacturing contracts or agents in some global markets, including but is not limited to:
African drug market could increase by 200% according to a realistic assumption, or by 300% according to an optimistic hypothesis within this same period. Based on African Pharmaceuticals Market Report of Frost and Sullivan of 2023, the pharmaceuticals market in Africa is expected to reach a business opportunity of $55 billion in 2030.
MENA region, pharma sales have reached an impressive $32 billion, with the Middle East accounting for $20.3 billion and North Africa for $10.7 billion. Saudi Arabia remains the biggest pharma market in the region according to 2023 sales numbers.
GCC market (Gulf countries) alone continues to expand at a rapid pace and is expected to almost double from $13.9 billion in 2018 to $25.7bn in the next decade as urbanization, an ageing population and chronic lifestyle-related diseases boost demand for pharmaceutical products.
